ArticleFrontiers in medicine2025
A drug response prediction method for single-cell tumors combining attention networks and transfer learning.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of AI in oncology: present applications and future horizons.NPJ precision oncology · 2026Review
- PKIDB-informed molecular profiling improves reproducible prediction of cancer kinase-inhibitor response.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurately predicting tumor cell line responses to therapeutic drugs is essential for personalized cancer treatment. Current methods using bulk cell data fail to fully capture tumor heterogeneity and the complex mechanisms underlying treatment responses. Methods: This study introduces a novel method, ATSDP-NET (Attention-based Transfer Learning for Enhanced Single-cell Drug Response Prediction), which combines bulk and single-cell data. The model utilizes transfer learning and attention networks to predict drug responses in single-cell tumor data, after pre-training on bulk cell gene expression data. A multi-head attention mechanism is incorporated to enhance the model's expressive power and prediction accuracy by identifying gene expression patterns linked to drug reactions. Results: ATSDP-NET outperforms existing methods in drug response prediction, as demonstrated on four single-cell RNA sequencing datasets. The model showed superior performance across multiple metrics, including recall, ROC, and average precision (AP). It accurately predicted the sensitivity and resistance of mouse acute myeloid leukemia cells to I-BET-762 and the sensitivity and resistance of human oral squamous cell carcinoma cells to cisplatin. Correlation analysis revealed a high correlation between predicted sensitivity gene scores and actual values (R = 0.888, Discussion: ATSDP-NET identifies critical genes linked to drug responses, confirming its predictions through differential gene expression scores and gene expression patterns. This method provides valuable insights into the mechanisms of drug resistance and offers potential for developing personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.